Archive Uncategorized

Uncategorized

$DXR Announces Rise in Kit Sales, New Device Sale

New York, NY, March 08, 2018 — Daxor Corporation, (NYSE MKT: DXR) an investment company with medical instrumentation and biotechnology operations, filed a Form N-CSR disclosing its schedule of portfolio holdings as of December 31, 2017.

In reporting its annual results for its medical device division, Daxor cited a 25% rise in kit sales related to cardiology use as well as an uptrend in overall kit sales for blood volume usage across all indications. In addition, the Company sold a new BVA-100 system to Self Regional Healthcare of Greenwood, South Carolina for use in their cardiology department following a successful pilot program.

Dr. Priya V. Kumar, a cardiologist at Self Regional was previously quoted as saying: “The BVA-100 has significantly improved our management of heart failure patients. It has proved to be a valuable tool in assessing volume status in difficult heart failure patients, especially those that are obese and those that are in renal failure. The BVA-100 has provided us with a great non-invasive way to assess a patient’s volume status accurately.”

Michael Feldschuh, CEO of Daxor stated: “Sales are rising — driven by the combination of successful outcome studies, focused sales efforts, and our client hospitals’ pressing need for improved readmission and mortality outcomes.”

Recent developments for the company in the past six months include inclusion in industry drug trials, outcome studies by researchers at academic institutions on blood volume usage in multiple indications, as well as interest from US Government agencies to improve ICU and heart failure outcomes. Soren Thompson, VP of Business Development stated: “We are working with a growing number of researchers and partners interested in improving outcomes through the use of precision blood volume analysis. The BVA-100 is widely viewed as the gold standard in this area and we are excited about the future potential for our clinical, research, and other partnerships. We are gratified there is increasing recognition of the urgent need for accurate individualized volume assessment to improve patient care and reduce hospital costs.”

Blood volume measurement is a fundamental tool for accurate diagnosis and treatment in a variety of medical and surgical conditions, such as congestive heart failure, critical care medicine and intensive care unit medicine, hypertension, syncope, pre-operative blood screening for hidden anemia, anemia in cancer patients, kidney failure, and hyponatremia, as well as additional conditions.

Daxor Corporation manufactures and markets the BVA-100 blood volume analyzer, which is used in conjunction with a single-use diagnostic kit. The BVA -100 is the only FDA-cleared instrument which quantifies blood volume with 98% accuracy with results available in under an hour. Over a dozen widespread medical conditions benefit from accurate volume assessment to guide therapy including heart failure and ICU use, the company has focused on sales in these areas.

Copies of the N-CSR form will be mailed to the Company’s shareholders and are filed with the SEC as well as on the Company’s website at http://www.daxor.com/wp-content/uploads/2018/03/Daxor-12-31-2017-FORM-N-CSR.pdf.

Contact Information:

Daxor Corporation:  Soren Thompson 212-330-8502 (Investor Relations) sthompson@daxor.com

Thursday, March 8th, 2018 Uncategorized Comments Off

$NETE Enables Global Commerce with Omni-Channel Payment Solution Platform

March 8, 2018

Increasing acceptance of smartphones for mobile payments coincides with emerging markets’ transition to non-cash transactions
Global mobile payments solutions market projected to reach $3.14 trillion by 2022, growing at a CAGR of 32 percent from 2017 to 2022
Innovative payment infrastructure and services are globally oriented but adaptable to unique requirements of each country
Omni-channel shoppers spend between 50 percent and 300 percent more than single shoppers

Net Element, Inc. (NASDAQ: NETE), a global technology company specializing in mobile payments and value-added transactional services, is growing rapidly as consumers and retailers around the globe embrace the security and ease of digital commerce. Net Element provides more than 100 electronic payment solutions for clients in 50 countries and plans to move into additional international markets. Several market research firms, including Statista (http://nnw.fm/kG8Wg), show that global transactions are soaring as consumers integrate mobile payment options into their daily routines.

Net Element and its team of engineers provide retailers with a disruptive, single commerce, all-in-one platform that supports multiple payment methods (http://nnw.fm/o0xEd). The company’s focus on developing innovative technology enables Net Element to grow its strategic position in a variety of emerging markets around the globe. Estimates of worldwide transaction volume vary depending on the research firm, but experts agree that mobile payment totals are expected to move into the billions of dollars (http://nnw.fm/hlq8X).

Retailers and customers alike can appreciate the omni-channel offerings of Net Element’s payment infrastructure, which allows the integration of in-store, online and mobile device apps that interact with the consumer’s evolving needs in mind (http://nnw.fm/mJo4n). A fully automated, encrypted payment solution that handles administration to configuration provides a secure and seamless cardholder transaction base for mobile purchases, while an exceptional collection of business analytics tools provides valuable information for today’s retailer that’s striving to make smarter decisions. Mobile payments are being used in a diverse range of business and consumer transactions, increasing exponentially as the proliferation of smart devices gains steam and consumers are offered the value-added benefits of mobile payments, according to Forrester Research Inc. (http://nnw.fm/I819v).

Net Element aims to grow transactional value by innovating productivity services for small to medium enterprises in the U.S. with its cloud-based restaurant and retail point-of-sale solution, Aptito. Internationally, Net Element’s strategy is to leverage its omni-channel platform to deliver flexible offerings to emerging markets with diverse banking, regulatory and demographic conditions. The company’s newest multi-channel payments platform – Netevia – provides end-to-end payment processing through user friendly APIs. In a news release, Andrey Krotov, Net Element’s chief technology officer, said that Netevia’s platform “delivers a blueprint and easy to use tools for global commerce and monetization, saving developers and merchants time and money with one provider and one integration across all sales channels.”

For more information, visit the company’s website at www.NetElement.com

More from NetworkNewsWire

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Thursday, March 8th, 2018 Uncategorized Comments Off

$RGNX to Participate in Upcoming Investor Conferences

ROCKVILLE, Md., March 07, 2018 — REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV^® Technology Platform, today announced that it will participate in the following March investor conferences:

Barclays Global Healthcare Conference
Date: Wednesday, March 14, 2018
Location: Loews Miami Beach Hotel, Miami, FL
Fireside chat: Wednesday, March 14, 2018 at 3:20 p.m. ET

Morgan Stanley Healthcare Corporate Access Day
Date: Tuesday, March 20, 2018
Location: Boston Harbor Hotel at Rowes Wharf, Boston, MA

A live webcast of the Barclays fireside chat can be accessed in the Investors section of REGENXBIO’s website at www.regenxbio.com. An archived replay of the webcast will be available on the same website for approximately 30 days following the presentation. In addition, REGENXBIO senior management will be holding one-on-one meetings at each of the conferences.

About REGENXBIO

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO’s NAV^® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

CONTACT:

Investors
Natalie Wildenradt, 646-681-8192
natalie@argotpartners.com

Media
Adam Pawluk, 202-591-4063
apawluk@jpa.com

Wednesday, March 7th, 2018 Uncategorized Comments Off

$PIXY Blockchain Use Case

ShiftPixy, Inc. (NASDAQ: PIXY), a disruptive workforce engagement platform provider, is leveraging blockchain as a digital ledger for all human capital transactions. Blockchain is being met with skepticism due to the lack of use cases.

ShiftPixy is a prime use case for implementing a private, centralized blockchain due to the security and privacy of the data that a blockchain affords. In business, human capital transactions contain some of the most crucial and sensitive personal information-namely, everything contained in the personnel records for an individual (including social security number, date of birth, driver’s license or passport details, bank account information, tax form elections, and more). Any data considered to be a human capital validation point or part of the hiring and onboarding process is being utilized and recorded in ShiftPixy’s blockchain ledger. The employee I-9 verification process, for example-one of the most stringent, rigorous, and penalty-laden compliance procedures-is positively impacted by blockchain utilization of biometric authentication and automatic verification of I-9 data, removing human error in the process of screening for fraudulent information. Scott Absher, President and CEO of ShiftPixy, stated, “We use blockchain technology in our ecosystem, because it is one of the most efficient tools available to help us protect our data from cyber interference. Any data considered to be a human capital validation point or part of the hiring and onboarding process is being utilized and recorded in ShiftPixy’s blockchain ledger.”

The security and ability for auditing transparency afforded by the integrated blockchain technology is paramount to protecting both the employee and the ShiftPixy job providers in the ShiftPixy ecosystem. Verification of that data on the blockchain allows both employers and auditing agencies to confidently validate additional criteria such as employment dates, and a candidate’s background (i.e. education, references, certifications, etc.), and share the verification status directly on multiple distributed sources within the blockchain, further underscoring the trust and accuracy of a candidate’s information and corporate compliance. Added benefits for data integrity include allowing employees and shift workers to rate experiences at a workplace-also recorded in the blockchain’s transparent ledger, which gives the peace of mind that the review or rating cannot be tampered with (i.e. neither shifters nor companies can pay to change or remove unfavorable ratings). Future implementation of blockchain technology within ShiftPixy’s technological ecosystem include the extended applications for payroll and real-time payments, and utilizing smart contracts for employment contracts, which facilitate the performance of credible, trackable, and irreversible transactions without third parties.

Learn More

To discover the power of ShiftPixy for your business please select one of our convenient webinar timeslots at:

https://www.shiftpixy.com/webinars/ or call us at 888-798-9200 to register.

Note of Clarification

To be clear, ShiftPixy has never, does not now and will never use its blockchain technology in any form of cryptocurrency or cryptocurrency related application.

About ShiftPixy

ShiftPixy (NASDAQ: PIXY) is a disruptive human capital management platform, revolutionizing employment in the Gig Economy by delivering a next-gen mobile engagement technology to help businesses with shift-based employees navigate regulatory mandates, minimize administrative burdens and better connect with a ready-for-hire workforce. With expertise rooted in management’s nearly 25 years of workers’ compensation and compliance programs experience, ShiftPixy adds a needed layer for addressing compliance and continued demands for equitable employment practices in the growing Gig Economy.

ShiftPixy Cautionary Statement

The information provided in this release includes forward-looking statements, the achievement or success of which involves risks, uncertainties, and assumptions. Although such forward-looking statements are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate. If any of the risks or uncertainties, including those set forth below, materialize or if any of the assumptions proves incorrect, the results of ShiftPixy, Inc., could differ materially from the results expressed or implied by the forward-looking statements we make. The risks and uncertainties include, but are not limited to, risks associated with the nature of our business model; our ability to execute the Company’s vision and growth strategy; our ability to attract and retain clients; our ability to assess and manage risks; changes in the law that affect our business and our ability to respond to such changes and incorporate them into our business model, as necessary; our ability to insure against and otherwise effectively manage risks that affect our business; competition; reliance on third-party systems and software; our ability to protect and maintain our intellectual property; and general developments in the economy and financial markets. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change, except as required by applicable securities laws. The information in this press release shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, and will not be deemed an admission as to the materiality of any information that is required to be disclosed solely by Regulation FD. Further information on these and other factors that could affect the financial results of ShiftPixy, Inc., is included in the filings on Forms 1-A and 10-K and in other filings we make with the Securities and Exchange Commission from time to time. These documents are available on the “SEC Filings” subsection of the “Investor Information” section of our website at https://ir.shiftpixy.com/financial-information/sec-filings.

Consistent with the SEC’s April 2013 guidance on using social media outlets like Facebook and Twitter to make corporate disclosures and announce key information in compliance with Regulation FD, ShiftPixy is alerting investors and other members of the general public that ShiftPixy will provide updates on operations and progress required to be disclosed under Regulation FD through its social media on Facebook, Twitter, LinkedIn and YouTube. Investors, potential investors, shareholders and individuals interested in our Company are encouraged to keep informed by following us on Facebook, Twitter, LinkedIn and YouTube.

Media Contact:
Clark Wilson
clark.wilson@shiftpixy.com
+1(949)-245-7250

Wednesday, March 7th, 2018 Uncategorized Comments Off

$VSQTF Mehdi Khimji Announces Exercise of Warrants to Acquire Additional Common Shares

LONDON, March 06, 2018 — Mr. Mehdi Khimji announces that he has exercised his warrants to purchase an aggregate of 3,333,334 common shares (the “Purchased Shares”) in the capital of Victory Square Technologies Inc. (“Victory Square” or the “Company”) (CSE:VST)(OTC:VSQTF)(FWB:6F6). The Purchased Shares were acquired for CDN$1.50 per Purchased Share, representing an aggregate exercise price of CDN$5,000,001 (the “Proceeds”).

The Purchased Shares represent approximately 5.3% of the outstanding Common Shares. When combined with the 6,666,667 Common Shares Mr. Khimji already owns, Mr. Khimji will hold an aggregate of 10,000,001 Common Shares, representing approximately 15.2% of the issued and outstanding Common Shares.

Mr. Khimji exercised the warrants to purchase the securities for investment purposes and may or may not purchase or sell securities of the Company, in the future on the open market or in private transactions, depending on market conditions and other factors. Depending on market conditions, general economic and industry conditions, the Company’s business and financial condition and/or other relevant factors, Mr. Khimji may develop other plans or intentions in the future.

A copy of the early warning report filed in connection with the transaction will be available on the Company’s profile on SEDAR at www.sedar.com or may be obtained by contacting Rick Whitworth at 972-444-9700.

Rick Whitworth
972-444-9700

Wednesday, March 7th, 2018 Uncategorized Comments Off

$ETST Subsidiary Receives Grant from the Government of Québec

Earth Science Tech, Inc. Announces it has Received its First Grant from the Government of Québec for its Three CBD Provisional Patents

DORAL, FL, March 07, 2018 — Earth Science Tech, Inc. (OTC: ETST) (“ETST” or the “Company”), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, as well as on R&D for certain medical devices, today announces that its Canadian subsidiary, Canna Inno Laboratories Inc. (the “Subsidiary”) has received a supporting grant for innovation in the pharmaceutical industry from the Ministère de l’économie, des sciences et de l’innovation of the Government of Québec.

ETST formed Canna Inno Laboratories Inc. in August 2017, a strategic Montreal, Canada-based company. The Subsidiary gave the Company a foothold in Québec and provided ETST with access to government grants, the first of which have just been approved.

This first grant is earmarked for the pre-launch processes on the Company’s three CBD-based nutraceutical provisional patent products, announced in 2017. The pre-launch process includes a series of pre-clinical in vitro trials to fight breast cancer and neurodegenerative disorders. Once the pre-launch has been completed, the results will be applied as a patent pending, the logical step following our provisional patent. During the application process, the products will be commercialised as nutraceutical.

The company also plans to apply for more funding under Canada’s Scientific Research and Experimental Development Tax Credit program among others.

Dr. Michel Aube, the Company’s CEO & CSO states, “The province of Quebec is a fertile terrain for biotech companies. The creativity of the people and the quality of the infrastructure are the fruits of a strong collaboration between governmental organizations and companies. We enjoy being a part of this great network to help assist our studies to create innovative alternative medicine.”

About Earth Science Tech, Inc. (ETST)

Earth Science Tech has among the highest quality, purity and full-spectrum high-grade hemp CBD (cannabidiol) oil on the market. Made using the superior supercritical CO2 liquid extraction, ETST’s CBD oil is 100% natural and organic. The company’s research, performed alongside the University of Central Oklahoma and DV Biologics laboratory, demonstrates that ETST is the top nutritional and dietary supplement brand for high-grade hemp CBD oil.

To learn more and to buy CBD Hemp Oil, please visit: www.EarthScienceTech.com

About Earth Science Pharmaceutical

Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Earth Science Pharmaceutical is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (sexually transmitted infections and/or diseases). Earth Science Pharmaceutical CEO Dr. Michel Aubé, a renowned scientist, is committed to help grow ETST in the medical and pharmaceutical industry.

To learn more please visit: www.EarthSciencePharmaceutical.com

About Cannabis Therapeutics

Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc. (ETST). Cannabis Therapeutics was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals, as well as other products & solutions. Cannabis Therapeutics’ mission it to help change the health care landscape by introducing its proprietary cannabis-cannabinoid-based products made for both the pharmaceutical and retail consumer markets worldwide.

To learn more please visit: www.CannabisThera.com

About KannaBidioiD

KannaBidioid, Inc. is wholly owned subsidiary of Earth Science Tech, Inc. (ETST). KannaBidioid is focused in the recreational space to manufacture and distribute vapes/e-liquids and gummy edibles in the recreational space formulated by its unique Kanna and CBD formula. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhance focus, and help with nicotine addiction based on their properties.

To learn more please visit: www.KannaBidioiDInc.com

SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:
Dave Demarest
305.546.7640 Office
Company Contact:
www.EarthScienceTech.com
Nickolas S. Tabraue
President, Director, Chief Operating Officer
305.615.2118 Office

Wednesday, March 7th, 2018 Uncategorized Comments Off

$DJACF Applies for Cannabis Oil License, Launches Innovative Extraction Program with Vitalis

TORONTO, March 7, 2018 – Hiku Brands Company Ltd. (“Hiku” or the “Company“) (CSE:HIKU), Canada’s first vertically-integrated cannabis brand house, is pleased to provide an update of the Company’s recent corporate development initiatives.

DOJA Applies for Cannabis Oil License and Signs Innovative Extraction Partnership Agreement with Vitalis

Hiku’s wholly-owned subsidiary DOJA Cannabis Ltd. (“DOJA“), a licensed cannabis producer under the Access to Cannabis for Medical Purposes Regulations (the “ACMPR“), submitted its application to Health Canada for the production of medical cannabis oils at its second site facility (the “FUTURE LAB“) located in Kelowna, British Columbia.

Hiku is also pleased to announce it has signed a strategic partnership agreement with Vitalis Extraction Technology Inc. (“Vitalis“), whereby Vitalis will advise on the build-out of DOJA’s extraction lab, partner on certain research and development initiatives, and supply the FUTURE LAB with Vitalis’ Q-90 supercritical CO2 extraction system – which is capable of processing up to 80 kg of cannabis flower per day into ultra-pure, exceptionally-clean, high-quality cannabis oils without the use of any toxic solvents. Vitalis is known as the leading manufacturer of high flow rate industrial supercritical CO2 extraction systems that are redefining the capabilities of traditional extraction methodologies.

“This is an important step for Hiku, the future of cannabis will be convenience and consistency, and the proliferation of dose-controlled consumption methods will be driven by oil and concentrate innovation,” said Alan Gertner, CEO of Hiku. “Vitalis has vast experience deploying supercritical CO2 extraction systems and is at the forefront of extraction innovation. We look forward to working with them to build out our state-of-the-art extraction lab and develop a diverse cannabis oil and concentrate offering.”

Once the FUTURE LAB is completed, Health Canada will be invited to conduct an inspection to secure an amendment permitting the production of cannabis oils.

Hiku Brings Prairies Tokyo Smoke Retail Expansion In-House After Prized Manitoba RFP Win

TS Brandco Holdings Inc. (“Tokyo Smoke“), Hiku’s wholly-owned subsidiary, with participation by BOBHQ, was conditionally awarded one of only four master retail licenses (the “License“) in Manitoba’s highly competitive Request for Proposal (“RFP“) process for the right to operate retail cannabis stores on February 16, 2018 (read more here). The License gives Tokyo Smoke the ability to operate legal retail cannabis stores and an online cannabis sales platform in Manitoba. Hiku is committed to expanding Tokyo Smoke’s retail locations in Alberta, Manitoba, and Saskatchewan through company owned and operated stores and plans on participating in future cannabis retail licensing processes across the country under the Tokyo Smoke and DOJA brands to significantly grow Hiku’s national retail footprint.

Keeping with the Company’s strategic vision for cannabis retail, Hiku has acquired all of the issued and outstanding shares of TS Prairie Retail Corp., an entity that previously held exclusive rights to establish “Tokyo Smoke” branded stores in Alberta, Manitoba, and Saskatchewan under a license agreement dated August 15, 2017, pursuant to a share purchase agreement dated March 6, 2018 in exchange for 4.2 million common shares in the capital of Hiku.

About Hiku

Hiku is focused on building a portfolio of iconic, engaging cannabis brands, unsurpassed retail experiences and handcrafted cannabis production. With a national retail footprint led byTokyo Smoke, craft cannabis production throughDOJA‘s ACMPR licensed grow, andVan der Pop‘s female-focused educational platforms, Hiku houses an industry-leading portfolio that sets the bar for cannabis brands in Canada.

Hiku’s wholly-owned subsidiary, DOJA Cannabis Ltd., is a federally licensed producer pursuant to the ACMPR, owning two production facilities in the heart of British Columbia’s Okanagan Valley. The company operates a network of retail stores selling coffee, clothing and curated accessories, across British Columbia, Alberta and Ontario.

Hiku has entered into supply partnerships with Aphria Inc. (TSX: APH) (OTCQB: APHQF) and WeedMD Inc. (TSXV: WMD) to ensure Hiku’s brands will be able to scale in 2018 and beyond.

About Vitalis

Vitalis is a Kelowna-based engineering and manufacturing company, producing the highest-flowing industrial supercritical CO2 extraction system for the cannabis market. The company’s core focus on innovation and design has vaulted it to the forefront of the market. Renowned for their reliability, scalability, and continuous operation, Vitalis systems are designed and manufactured in accordance with ASME and CSA Standards for Boiler, Pressure Vessel and Pressure Piping Code. The vessels are stamped with a CRN and NB registration number confirming that the vessels meet code and have been inspected by an Authorized Inspector. With systems on three continents, Vitalis has the most deployments of industrial CO2 supercritical extractors into the cannabis industry. Vitalis was recently voted Top Extraction Equipment at the 2017 Lift Canadian Cannabis Awards. For more information, visit their website at www.vitaliset.com.

Regarding Forward-Looking Information

This news release contains statements that constitute “forward-looking statements”. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Hiku’s actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur.

Forward-looking statements in this document include statements regarding the ongoing relationship between the Company and Vitalis, the performance of Vitalis products and technology, the Company and Tokyo Smoke’s intention to expand retail locations in the Prairies, and the Company’s participation in future cannabis retail licensing processes. By their nature, forward-looking statements are based on the opinions and estimates of management at the date the information is made, and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Hiku is not under any obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

The Canadian Securities Exchange has not approved nor disapproved the contents of this news release.

Wednesday, March 7th, 2018 Uncategorized Comments Off

$CLSD Announces Proposed Public Offering of Common Stock

ALPHARETTA, Ga., March 06, 2018 — Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced that it intends to offer and sell, subject to market conditions, $75 million of shares of its common stock in an underwritten public offering. All of the shares of common stock to be sold in the offering will be offered by Clearside. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

Clearside intends to use the net proceeds of the offering to prepare and submit an NDA for suprachoroidal CLS-TA for the treatment of patients with macular edema associated with non-infectious uveitis and to invest in commercialization and marketing of suprachoroidal CLS-TA, if approved. In addition, Clearside intends to use the net proceeds to continue its Phase 3 SAPPHIRE clinical trial for its RVO program, complete its Phase 2 TYBEE clinical trial for its DME program and initiate its second Phase 3 TOPAZ clinical trial for its RVO program, as well as for continued research and development of its earlier-stage programs, working capital and general corporate purposes.

J.P. Morgan Securities LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering. Stifel, Nicolaus & Company, Incorporated is acting as a passive book-running manager and Needham & Company, LLC and Wedbush Securities Inc. are acting as co-managers for the offering. Clearside intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering.

A shelf registration statement relating to the shares of common stock offered in the public offering described above was filed with the Securities and Exchange Commission (SEC) on July 3, 2017 and declared effective by the SEC on July 13, 2017. The offering will be made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus, when available, may also be obtained by contacting J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by email at prospectus-eq_fi@jpmchase.com, or by phone at (866) 803-9204; or Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, or by phone at (631) 274-2806, or by fax at (631) 254-7140.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Clearside Biomedical, Inc.

Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a publicly traded, ophthalmic biopharmaceutical company that envisions a world without blindness. Clearside relentlessly pursues transformative, elegant, precise solutions to restore and preserve vision. Clearside is developing advanced clinical and nonclinical candidates using a proprietary treatment approach offering unprecedented access to the back of the eye through the suprachoroidal space (SCS™). This offers potentially meaningful treatment benefits to patients suffering from sight threatening diseases like uveitis, retinal vein occlusion, diabetic macular edema and wet age-related macular degeneration.

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for Clearside, including statements about the Clearside’s anticipated public offering, anticipated use of proceeds and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all, uncertainties inherent in the initiation of future clinical trials and such other factors as are set forth in the risk factors detailed in Clearside’s Annual Report on Form 10-K filed with the SEC on March 16, 2017 and other filings with the SEC under the heading “Risk Factors.” In addition, the forward-looking statements included in this press release represent Clearside’s views as of the date hereof. Clearside anticipates that subsequent events and developments will cause Clearside’s views to change. However, while Clearside may elect to update these forward-looking statements at some point in the future, Clearside specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Clearside’s views as of any date subsequent to the date hereof.

Contacts:
Stephen Kilmer
Investor Relations
(678) 270-3631
stephen.kilmer@clearsidebio.com

Charles Deignan
Chief Financial Officer
(678) 270-4005
charlie.deignan@clearsidebio.com

Tuesday, March 6th, 2018 Uncategorized Comments Off

$AMTX Completes Operation of Cellulosic Ethanol Integrated Demonstration Unit

CUPERTINO, CA / March 6, 2018 / Aemetis, Inc. (NASDAQ: AMTX) announced today that the company successfully built and operated an integrated demonstration unit for more than 120 days of continuous operations with 94% uptime, meeting the requirements for a federal USDA 9003 Biorefinery Assistance Program guaranteed loan.

In partnership with its key technology providers InEnTec and LanzaTech, Aemetis successfully optimized the integration of an advanced arc furnace and gas fermentation technologies to convert waste biomass into low carbon, renewable cellulosic ethanol and fish meal. The unit was built at the InEnTec Technology Center in Richland, Washington and demonstrated the fully integrated system, including biomass handling, gasification, gas clean up, waste treatment and distillation systems.

“The completion of the successful operation of the demonstration unit is the final technology step in securing a USDA loan guarantee for the $158 million cellulosic ethanol plant Aemetis is building in Riverbank, California,” said Eric McAfee, Chairman and CEO of Aemetis. “We believe that the integration of these technologies, and the high yields generated by the unit, demonstrate that Aemetis can successfully produce high value cellulosic ethanol from the 1.6 million tons of waste orchard wood and other renewable feedstocks in the Central Valley. With plans to expand the Riverbank plant and construct additional plants, Aemetis plans to be a leader in supplying California’s low carbon fuels mandates.”

With a 20-year feedstock supply agreement and a 55-year lease already signed, the 12 million gallon per year Riverbank plant is expected to begin operations in 2019.

For the demonstration unit, Aemetis used waste orchard wood and nut shells from almond and walnut trees as feedstock, gasified the biomass using a high temperature plasma gasification system to produce synthesis gas (“syngas”), cooled and cleaned the syngas, and supplied the syngas to a patented gas fermentation bioreactor to produce an ethanol broth. The broth was subsequently distilled to produce commercial grade ethanol.

About Aemetis

Headquartered in Cupertino, California, Aemetis is an advanced renewable fuels and biochemicals company focused on the acquisition, development and commercialization of innovative technologies that replace traditional petroleum-based products by the conversion of ethanol and biodiesel plants into advanced biorefineries. Founded in 2006, Aemetis owns and operates a 60 million gallon per year ethanol production facility in California’s Central Valley, near Modesto. Aemetis also owns and operates a 50 million gallon per year renewable chemical and advanced fuel production facility on the East Coast of India producing high quality distilled biodiesel and refined glycerin for customers in India, the US and Europe. Aemetis operates a research and development laboratory, and holds a portfolio of patents and related technology licenses for the production of renewable fuels and biochemicals. For additional information about Aemetis, please visit www.aemetis.com.

Safe Harbor Statement

This news release contains forward-looking statements, including statements regarding our assumptions, projections, expectations, targets, intentions or beliefs about future events or other statements that are not historical facts. Forward-looking statements in this news release include, without limitation, statements relating to the production or effectiveness of the demonstration facility, and the construction and operation of the cellulosic ethanol facility. Words or phrases such as “anticipates,” “may,” “will,” “should,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “showing signs,” “targets,” “will likely result,” “will continue” or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on current assumptions and predictions and are subject to numerous risks and uncertainties. Actual results or events could differ materially from those set forth or implied by such forward-looking statements and related assumptions due to certain factors, including, without limitation, competition in the ethanol, biodiesel and other industries in which we operate, commodity market risks including those that may result from current weather conditions, financial market risks, customer adoption, counter-party risks, risks associated with changes to federal policy or regulation, and other risks detailed in our reports filed with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2016, and in our subsequent filings with the SEC. We are not obligated, and do not intend, to update any of these forward-looking statements at any time unless an update is required by applicable securities laws.

External Investor Relations Contact:

Kirin Smith
PCG Advisory Group
(646) 863-6519
ksmith@pcgadvisory.com

Company Investor Relations/ Media Contact:

Todd Waltz
(408) 213-0940
investors@aemetis.com

Tuesday, March 6th, 2018 Uncategorized Comments Off

$PVOTF Announces Acquisition of Thrudermic, LLC

Vancouver, British Columbia–(March 6, 2018) – Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (“Pivot” or the “Company”) is pleased to announce the acquisition of Thrudermic, LLC (“TDL” or “Thrudermic”), a privately held North Carolina company. Pivot previously announced a licensing agreement with Thrudermic but has decided to exercise its option to acquire 100% of TDL. Pivot will pay $1.00 (USD) for all of the issued and outstanding units of Thrudermic, and issue an aggregate of 500,000 common shares in the capital of Pivot to Dr. Joseph Borovsky and Dr. Leonid Lurya for their intellectual property portfolio, including patents, good will and know-how in connection with the TDL Transdermal Nanotechnology. Dr. Borovsky, has been appointed Pivot’s Vice President, Product Formulation, and Dr. Lurya has been appointed Executive Director, Product Formulation.

The TDL Transdermal Nanotechnology is intended for the formulation and delivery of dosable bio-cannabis products. On behalf of Pivot, Thrudermic recently filed three additional patent applications related to improved formulation and delivery for new routes of administration of cannabinoids and will increase the number of products in the Company’s pipeline.

“Thrudermic is very excited to become part of the Pivot organization. Our lipid-based nano-dispersion technology is well suited for the emerging cannabis industry. Pivot’s goal is to increase cannabinoid bioavailability, drug release rates and improve product stability, and consumers should be able to confidently take correct and accurate doses to help meet their health and wellness needs,” states Dr. Borovsky.

Dr. Borovsky, formerly the director of research and development for Mead Corporation, received his Bachelor of Science degree in Chemistry from UCLA and his Ph.D. in Physical Organic Chemistry from the University of Massachusetts at Amherst. He also completed a year of post-doctoral research in Medicinal Chemistry at Washington State University College of Pharmacy and was a Research Fellow in Synthetic Organic Chemistry at Harvard University. Dr. Lurya is the inventor of Thrudermic transdermal technology and has authored several patents. He received his MD from the Moscow Medical Institute No. 2, Russia, and then completed his PhD in Biophysics, Chemical Physics Department at the Weizmann Institute of Science, Israel.

Dr. Patrick Frankham, Pivot’s CEO, comments, “Thrudermic is Pivot’s fourth disruptive formulation and delivery platform for cannabinoids. We are thrilled that Dr. Borovsky and Dr. Lurya have agreed to join us to develop and commercialize therapeutic bio-cannabis products. They are highly experienced formulations experts with many years of pharmaceutical industry know-how. Pivot continues to position itself as a leader in the delivery of dosable bio-cannabis, something that consumers and regulatory agencies will demand as legalization occurs.”

About Pivot Pharmaceuticals Inc.

Pivot Pharmaceuticals Inc. is an emerging biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using innovative drug delivery platform technologies. Pivot’s wholly-owned medical cannabis products division, Pivot Green Stream Health Solutions Inc. (“PGS” or Pivot Green Stream), conducts research, development and commercialization of cannabinoid-based nutraceuticals and pharmaceuticals. PGS has acquired worldwide rights to BiPhasix™ Transdermal Drug Delivery platform technology (topical); Solmic Solubilisation technology (oral) and Thrudermic Transdermal Nanotechnology (transdermal) for the delivery and commercialization of cannabinoid, cannabidiol (CBD), and tetrahydrocannabinol (THC)-based products. PGS’ initial product development candidates will include topical treatments for women’s sexual dysfunction (PGS-N005), as well as psoriasis (PGS-N007), and an oral product (PGS-N001) for cancer supportive care. PGS will seek to register these as Natural Health Products (NHP) for consumers. Products following the NHP pathway have shorter development cycles and can generate revenue faster than traditional pharmaceuticals. For more information please visit www.PivotPharma.com.

Cautionary Statement

Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as anticipate, believe, estimate, expect, intend, and similar expressions, as they relate to Pivot or Pivot Green Stream, or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, such as the level of business and consumer spending, the amount of sales of Pivot’s products, the competitive environment within the industry, the ability of Pivot to continue to expand its operations, the level of costs incurred in connection with Pivot’s expansion efforts, economic conditions in the industry, and the financial strength of Pivot’s customers and suppliers. Pivot does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.

Contact:

Pivot Pharmaceuticals Inc.
Patrick Frankham, PhD, MBA
Chief Executive Officer
Tel: (514) 943-1899
Email: Info@PivotPharma.com

Corporate Communications Contact:

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Tuesday, March 6th, 2018 Uncategorized Comments Off

$PVOTF Closes C$5M Private Placement of Convertible Debentures

VANCOUVER, British Columbia, March 05, 2018 — via NetworkWire – Pivot Pharmaceuticals Inc. (CSE:PVOT) (OTCQB: PVOTF) (“Pivot” or the “Company”) is pleased to announce the closing of its previously announced private placement of convertible debentures for aggregate gross proceeds of C$5 million (the “Offering”). The Company intends to use the net proceeds of the Offering for the development of its pipeline of products, intellectual property acquisitions, and for working capital and general corporate purposes.

Pursuant to the Offering, the Company issued a total of C$5 million of 10% senior secured convertible debentures (the “Convertible Debentures”) which will mature 12 months following the date of their issuance and will be convertible at the option of the holder for a period of 12 months into common shares of the Company (“Common Shares”) at a conversion price of C$1.74 per Common Share (the “Conversion Price”), subject to adjustment of the Conversion Price in certain events.

Beginning on the date that is four months and one day following the issuance of the Convertible Debentures, the Company may force the conversion of the principal amount of the then outstanding Convertible Debentures at the Conversion Price on not less than 30 days’ notice should the daily volume weighted average trading price of the Common Shares be greater than C$2.50 for any 20 consecutive trading days on the Canadian Stock Exchange, or such other exchange as the Common Shares are principally traded.

In connection with the Offering, Origin Merchant Securities Inc. received a finder’s fee of C$300,000, being 6% of the gross proceeds from the Offering and 172,413 non-transferable compensation warrants, being 6% of the gross proceeds from the Offering divided by the Conversion Price. Each compensation warrant entitles the holder to purchase one Common Share at the Conversion Price for a period of three years following the Closing of the Offering. All securities issued in connection with the Offering are subject to a four month hold period. For further details on the Offering, please refer to the Company’s news release dated February 27, 2018.

About Pivot Pharmaceuticals Inc.

Pivot Pharmaceuticals Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using innovative drug delivery platform technologies. Pivot’s wholly-owned medical cannabis products division, Pivot Green Stream Health Solutions Inc. (“PGS” or “Pivot Green Stream”), conducts research, development and commercialization of cannabinoid-based nutraceuticals and pharmaceuticals. PGS has acquired worldwide rights to BiPhasix™ Transdermal Drug Delivery platform technology (topical), Solmic Solubilisation technology (oral) and Thrudermic Transdermal Nanotechnology (transdermal) for the delivery and commercialization of cannabinoid, cannabidiol (CBD), and tetrahydrocannabinol (THC)-based products. PGS’ initial product development candidates will include topical treatments for women’s sexual dysfunction (PGS-N005), as well as psoriasis (PGS-N007), and an oral product (PGS-N001) for cancer supportive care. For more information please visit www.PivotPharma.com

Cautionary Statement

Contact:

Pivot Pharmaceuticals Inc.
Patrick Frankham, PhD, MBA
Chief Executive Officer
Tel: (514) 943-1899
Email: info@pivotpharma.com

Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Monday, March 5th, 2018 Uncategorized Comments Off

$CIIX Announces New Company and Focused Financial Future

March 5, 2018

CIIX announces spinoff of all hemp-related assets into a single private company
CIIX shifts primary focus to core financial services, including cryptocurrency and blockchain technology

ChineseInvestors.com, Inc. (OTCQB: CIIX) has become the premier financial information website providing real-time market commentary, analysis and education-related services to Chinese-speaking investors. In 2018, the company is strategically focusing on building its core financial services business. CIIX has announced a spinoff of all hemp-related assets as the company explores new ways to expand.

CIIX announced plans to spin off all hemp-related assets into a single private company. CBD Biotechnology Co. Ltd., ChineseHempOil.com, Inc. and Hemp Logic Inc. will be combined into a single private company. Shareholders have the opportunity to take advantage of this dividend. CIIX CEO Warren Wang is encouraging holders of CIIX preferred stock to convert into common before May 31, 2018, the date of the spinoff.

The subsidiaries are well positioned to achieve significant growth. This spinoff is part of the groundwork to capitalize on the growing demand for CBD-based nutrition and health products in the U.S. and China. In January, these subsidiaries made a combined $100,000. The progress of the newly formed company will be overseen by CIIX, but the spinoff of CBD-focused assets will allow CIIX to focus on core financial services, including cryptocurrency and blockchain technology.

Since 1999, CIIX has been leading the way in providing financial information and education for Chinese-speaking investors. With the formation of the new company, CIIX plans to focus on its new cryptocurrency division and core financial education business, including ‘Bitcoin MultiMillionaire’, a daily newscast broadcast by CIIX as a free bitcoin education site in the Chinese language. The broadcast was launched in recognition of the growing interest in cryptocurrency among Chinese investors. CIIX provides reliable market information to help investors make informed decisions to meet their personal financial goals.

For more information, visit the company’s website at www.ChineseInvestors.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Monday, March 5th, 2018 Uncategorized Comments Off

$ETST Update on Human Trials of CBD-based Formula Targeting Opioid Crisis

NEW YORK, March 05, 2018 – via NetworkWire — NetworkNewsWire (“NNW”), a multifaceted financial news and publishing company for business, today announces the audio version of a recent Earth Science Tech, Inc. (OTC: ETST) press release titled “Earth Science Tech, Inc. Finalizes Plans for Human Trials on New CBD-Based Formula Targeting Opioid Addiction Epidemic.”

To hear the Earth Science Tech, Inc. AudioPressRelease (APR) version, visit: http://nnw.fm/uR4QO

To read the original press release, visit: http://nnw.fm/YU5hv

About Earth Science Tech, Inc.

About NetworkNewsAudio

NetworkNewsAudio (NNA) , a NetworkNewsWire (NNW) Solution, allows you to sit back and listen to market updates, CEO interviews and a Company AudioPressRelease (APR). These audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio (NNA) is another NetworkNewsWire (NNW) Solution that can assist your company by cutting through the overload of information in today’s market, NNA brings its clients unparalleled visibility, recognition and brand awareness. NetworkNewsWire (NNW) is where news, content and information converge. NetworkNewsWire (NNW) is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public. With an ever-growing distribution network of more than 5,000 key syndication outlets across the nation.

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets, (3) enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge. For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications Contact:

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Monday, March 5th, 2018 Uncategorized Comments Off

$ZSAN Issuance of New U.S. Patent Covering M207 in Migraine

Patent extends proprietary position of M207 to 2037

FREMONT, Calif., March 02, 2018 — Zosano Pharma Corp. (NASDAQ:ZSAN) (“Zosano” or the “Company”) a clinical stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to subjects using its proprietary Adhesive Dermally-Applied Microarray (“ADAM™”) technology, today announced that the previously announced Notice of Allowance of our patent application titled “Method of Rapidly Achieving Therapeutic Concentrations of Triptans for Treatment of Migraines” has resulted in the issuance of a U.S. patent 9,918,932. The inventors were Dr. Mahmoud Ameri, Dr. Don Kellerman, Dr. Yi Ao, and Dr. Peter Dadonna, all of whom are current or former employees of Zosano. In February 2017, Zosano reported positive pivotal data from our Zotrip Phase 2/3 trial, in which subjects treated with the 3.8mg dose of M207 achieved statistical significance on the co-primary endpoints. The newly issued patent contains claims generated from formulation, preclinical and clinical studies, and highlights the unique aspects of the Zosano technologies and their applicability for treatment of migraine.

“We are pleased to have this important expansion of our patent estate for M207,” said John Walker, Chairman and Chief Executive Officer of Zosano. “This issuance supports our intellectual property strategy for our ADAM technology, and specifically M207. We intend to pursue similar patent coverage for future products that Zosano develops internally, and in future partnerships.”

Zosano’s patent estate additionally includes other granted U.S. and foreign patents and pending patent applications covering our ADAM technology, including our microneedle technology, drug formulations, methods of use and applicators.

About M207

M207 is our proprietary formulation of zolmitriptan delivered utilizing Zosano’s proprietary Adhesive Dermally-Applied Microarray, or ADAM technology. Zosano’s ADAM technology consists of titanium microprojections coated with drug, and in the case of M207, our formulation of zolmitriptan. Our ADAM technology delivers drug by penetrating the stratum corneum and allowing drug to be absorbed into the microcapillary system of the skin. In February 2017, the Company announced statistically significant results from the ZOTRIP trial, which demonstrated that the 3.8mg dose of M207 met both co-primary endpoints, achieving pain freedom and most bothersome symptom freedom at 2 hours.

About Zosano Pharma

Zosano Pharma Corporation is a clinical stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using our proprietary Adhesive Dermally-Applied Microarray, or ADAM technology. The Company recently announced positive results from our ZOTRIP study that evaluated M207, which is our proprietary formulation of zolmitriptan delivered via our ADAM technology, as an acute treatment for migraine. Zosano is focused on developing products where rapid administration of established molecules with known safety and efficacy profiles provides an increased benefit to patients, for markets where patients remain underserved by existing therapies. The Company anticipates that many of its current and future development programs may enable the Company to utilize a regulatory pathway that would streamline clinical development and accelerate the path towards commercialization. Learn more at www.zosanopharma.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding the timing of expected clinical development milestones, sufficiency of our capital resources and need for future funding and other future events and expectations. Readers are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “might,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “forecast,” “designed,” “goal,” “unaudited,” “approximately” or the negative of those words or other comparable words to be uncertain and forward-looking. These statements are subject to risks and uncertainties that are difficult to predict and actual outcomes may differ materially. These include risks and uncertainties, without limitation, associated with the process of discovering, developing and commercializing products that are safe and effective for use as human therapeutics, risks inherent in the effort to build a business around such products and other risks and uncertainties described under the heading “Risk Factors” in the Company’s most recent annual report on Form 10-K.. Although we believe that the expectations reflected in these forward-looking statements are reasonable, we cannot in any way guarantee that the future results, level of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. All forward-looking statements are based on information currently available to Zosano and Zosano assumes no obligation to update any such forward-looking statements.

Zosano Contact:
Georgia Erbez
Chief Business Officer and
Chief Financial Officer
510-745-1200

Friday, March 2nd, 2018 Uncategorized Comments Off

$VSQTF Demonstrates Success in Recent Months – NetworkNewsBreaks

February 27, 2018

Stock price increased by more than $3.00 in a two-month period
Various acquisitions and partnerships in 2018
Focused on incubating the new century’s technology giants

From numerous recent acquisitions to a stock price that has climbed dramatically in the past year, it’s an exciting time for blockchain-focused venture builder Victory Square Technologies Inc. (CSE: VST) (OTC: VSQTF) (FRANKFURT: 6F6) (WKN: A2AKL8).

Engaged in funding and empowering entrepreneurs to implement cutting-edge blockchain solutions, Victory Square is in the business of incubating a new generation of technology titans. The company’s diversified portfolio includes investment interests in the gaming, health care, artificial intelligence and virtual reality sectors, as well as others, and Victory Square’s portfolio companies are effectively disrupting a wide range of sectors across the global economy.

So far in 2018, Victory Square has announced various important acquisitions, including a 100 percent acquisition of established mobile games studio V2 Games Inc. (http://nnw.fm/39sNF), a 31.35 percent acquisition of emerging payment processing company PayVida Solutions Inc. (http://nnw.fm/IE4lM), and a 23.1 percent acquisition of emerging blockchain-focused fintech company Cassia Research Inc. (http://nnw.fm/1t9LV). The company has further forged various exciting strategic partnerships this year.

Victory Square’s stock has enjoyed an impressive boost in a short amount of time, climbing from $0.298 in October 2017 to an impressive $3.32 by December 2017. As of February 27, the company’s price has remained well above $2.00 per share.

Victory Square operates on the idea that impactful companies are built upon experimentation of bold ideas, and entrepreneurs working with the company have invaluable access to Victory Square’s education programs, global mentor network, distribution partners, creative workspaces, operational support and other resources to help them scale on an international level.

The company’s impressive brag sheet includes assisting more than 1,000 entrepreneurs and more than 500 startups to date, helping these entities collectively raise over $100 million and create more than 1,000 jobs.

Victory Square recognizes blockchain as the new major technology and the next key platform for innovation, with the ability to revolutionize the interconnections and operations of business and social structures. Leveraging its extensive expertise and standout prowess in building companies, Victory Square is hard at work identifying, incubating, advising and investing in the industry’s very best blockchain entrepreneurs.

For more information, visit the company’s website at www.VictorySquare.com

More from NetworkNewsWire

About NetworkNewsWire

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Friday, March 2nd, 2018 Uncategorized Comments Off

$CIIX Featured on MoneyTV with Donald Baillargeon, 3/2

LOS ANGELES, CA / March 2, 2018 / CBD oil, the blockchain, water cleanup, solar and roofing, cannabis business, Chinese investors, who want the POTUS job; this week on MoneyTV with Donald Baillargeon. MoneyTV is the internationally syndicated television program all about money and what makes it happen, (http://www.moneytv.net), featuring informative interviews with company CEOs and executives, providing insights into their operations and outlooks for their futures.

Free information packages from the featured companies can be requested by sending an email to info@moneytv.net.

The television program can also be viewed online immediately at www.moneytv.net.

Featured companies on this week’s program include:

Chineseinvestors.com, Inc. (OTCQB: CIIX) CEO Warren Wang spoke of the company’s history and the recent focus on CBD oil products and cryptocurrency investor education.

Singlepoint, Inc. (OTCQB: SING) CEO Greg Lambrecht announced they have acquired a $1 million stake in cannabis cultivation land in California.

Solar Integrated Roofing Corporation (OTC PINK: SIRC) President David Savarese discussed deals with Angie’s List and Home Advisor.

Premier Biomedical, Inc. (OTC PINK: BIEI) CEO William Hartman discussed several aspects of the company’s business model.

OriginClear, Inc. (OTCQB: OCLN) CEO Riggs Eckelberry announced a water cleanup contract in Spain.

The Advocacy Network Founder Karl Schilling discussed the elements of achieving financial independence.

A complete menu of TV listings is available at the MoneyTV web site, http://www.moneytv.net.

MoneyTV Executive Producer and Anchor Donald Baillargeon is also the host of MoneyRap Radio, http://www.moneyrap.com and the television program Crowdfund Television, http://www.crowdfundtelevision.com.

MoneyTV with Donald Baillargeon television program, Copyright MMXVIII, all rights reserved. MoneyTV does not provide an analysis of companies’ financial positions and is not soliciting to purchase or sell securities of the companies, nor are we offering a recommendation of featured companies or their stocks. Information discussed herein has been provided by the companies and should be verified independently with the companies and a securities analyst. MoneyTV provides companies a 3 to 4-month corporate profile with multiple appearances for a cash fee of $11,995.00 to $17,250.00, does not accept company stock as payment for services, does not hold any positions, options or warrants in featured companies. The information herein is not an endorsement by Donald Baillargeon, the producer, publisher or parent company of MoneyTV.

Contact:

Donald Baillargeon
info@moneytv.net
949 388 5267

Friday, March 2nd, 2018 Uncategorized Comments Off

$EAST Redneck Riviera Whiskey’s John Rich Throws a Party with Top Accounts in South Dakota

DEADWOOD, S.D. & PORTLAND, Ore.

Eastside Distilling, Redneck Riviera and RNDC Host a Night of Great Entertainment to Launch Redneck Riviera Whiskey Available Now in South Dakota

Eastside Distilling, Inc. (NASDAQ: EAST), makers of award-winning craft spirits, and partner John Rich hosted a launch party to celebrate Redneck Riviera Whiskey (“RRW”) being available in South Dakota. Republic National Distributing Company (“RNDC”) has recently commenced distribution of Redneck Riviera Whiskey in South Dakota. Redneck Riviera Whiskey is a collaboration of Eastside Distilling and John Rich, the multi-platinum country-music artist and one-half of the award-winning duo Big & Rich. Please visit www.redneckriviera.com for more information on the brand. Download high-resolution images from the event here.

John Rich at the Redneck Riviera Whiskey Launch Party at the Deadwood Mountain Grand Resort on February 23, 2018. Photo: Nick Hubbard

The SRO crowd dominated by various key liquor industry executives, media representatives and others took in a John Rich exclusive and intimate performance on Friday, February 23, 2018 at the Deadwood Mountain Grand Event Stage at the Deadwood Mountain Grand Resort in Deadwood, South Dakota.

“As I have previously stated, I share a great kinship with the history and the people of South Dakota,” commented John Rich. “My musical partner, Big Kenny Alphin and I have been inspired as songwriters by the history of the state, as well as by men like Vietnam veteran Niles Harris who inspired one of our songs and our commitment to Folds of Honor to help pay for college tuition for kids who have had a parent killed in combat. I can’t think of a better place and venue than Deadwood, South Dakota to celebrate with friends the rollout of our great American blend in this beautiful and historic state.”

Redneck Riviera Whiskey is currently now available or will be available very shortly in Texas, Louisiana, Alabama, Georgia, Mississippi, Florida, North Carolina, North and South Dakota, Oregon, Tennessee, Oklahoma and Nebraska. The list of states where Redneck Riviera Whiskey is distributed will grow as the product rollout continues.

About Redneck Riviera

Redneck Riviera is a privately held lifestyle brand that celebrates America’s hard-working men and women. Built for people who live to turn up the music and have fun with friends and family, Redneck Riviera is America’s ‘Work Hard, Play Hard’ brand that offers something for everyone who likes to rock the red, white and blue all year long. Launched in 2014, the brand brings these values to life through footwear, apparel, hospitality, food, spirits and licensed products in a variety of categories. Redneck Riviera has expanded its reach with the opening of honky-tonk bar Redneck Riviera Las Vegas and a Nashville location opening in 2018. More information can be found here.

About Eastside Distilling

Eastside Distilling, Inc. (NASDAQ: EAST) has been producing high-quality, award-winning craft spirits in Portland, Oregon since 2008. The company is distinguished by its highly decorated product lineup that includes Burnside Bourbon, West End American Whiskey, Goose Hollow Reserve, Below Deck Rums, Portland Potato Vodka, Hue-Hue Coffee Rum and a distinctive line of fruit infused spirits. Eastside Distilling is majority owner of Big Bottom Distilling (makers of The Ninety One Gin, Navy Strength Gin and Delta Rye whiskey) and the Redneck Riviera Whiskey Co. All Eastside, Big Bottom and Redneck Riviera spirits are crafted from natural ingredients for quality and taste. Eastside’s MotherLode Bottling subsidiary is one of the Northwest’s leading independent spirit bottlers and ready-to-drink canners. For more information visit: www.eastsidedistilling.com or follow the company on Twitter and Facebook.

Important Cautions Regarding Forward-Looking Statements

Certain matters discussed in this press release may be forward-looking statements. Such matters involve risks and uncertainties that may cause actual results to differ materially, including the following: changes in economic conditions; general competitive factors; acceptance of the Company’s products in the market; the Company’s success in obtaining new customers; the Company’s success in product development; the Company’s ability to execute its business model and strategic plans; the Company’s success in integrating acquired entities and assets, and all the risks and related information described from time to time in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the financial statements and related information contained in the Company’s Annual Report on Form 10-K and interim Quarterly Reports on Form 10-Q. Examples of forward-looking statements in this release may include statements related to our strategic focus, product verticals, anticipated revenue, and profitability. The Company assumes no obligation to update the cautionary information in this release.

Media Contact:
Wortman Works Media & Marketing
Jules Wortman, 615-260-9985
jwortman@wortmanworks.com
or
Company Contact:
Eastside Distilling
Steve Shum, CFO
971-888-4264
inquiries@eastsidedistilling.com
or
Investors:
Lytham Partners, LLC
Robert Blum, Joe Diaz or Joe Dorame
602-889-9700
east@lythampartners.com

Thursday, March 1st, 2018 Uncategorized Comments Off

$MNGA European Commission Awards European Joint Venture a $7.2 Million Grant

European Government Funding Expected to Expand Scope of German-Based Biofuels Pilot Program in 2018

TAMPA, FL–(March 01, 2018) – MagneGas Corporation (“MagneGas” or the “Company”) (NASDAQ: MNGA), a leading clean technology company in the renewable resources and environmental solutions industries, announced today that its European joint venture with Infinite Fuels, GmbH has been awarded a EUR6.0 million ($7.2 million USD) grant from the Executive Agency for Small and Medium-sized Enterprises (EASME), a department within the European Commission. The grant application was made by Infinite Fuels through an Eco-Innovation funding initiative within the Energy, Environment, and Resources Department of EASME. The grant approval process is expected to be finalized and funds made available in mid-2018.

“This grant is a major opportunity for MagneGas, together with our joint venture partners, to take a leading role in providing clean technology solutions within the European Union at scale,” commented Ermanno Santilli, CEO of MagneGas. “We have spent almost two years working to help make this possible. We feel very fortunate that with the help of our advisors at Ernst & Young in Europe, our joint venture partnership was able to successfully navigate the process of passing the evaluation phase of the grant approval processes with EASME. This grant opportunity is an excellent example of the European Union’s commitment to funding emerging clean technology projects. This funding is expected to play a key role in our ability to attract additional capital in Europe in the immediate term, which is expected to accelerate and expand the scope of our operational launch in Germany in 2018.”

“This is a major breakthrough for MagneGas and our joint venture partners from a capital formation perspective,” commented Scott Mahoney, CFO of MagneGas. “We had a very clear understanding of the various capital channels that Infinite Fuels could pursue in Europe when we elected to expand our relationship to a full joint venture partnership during our meetings last month. We are currently working on additional non-dilutive capital with other European government bodies, as well as prospective equity partners for Infinite Fuels. Most importantly, we see this as the ideal template to source introductions to cornerstone clients combined with non-dilutive capital through joint venture partnerships to accelerate our growth into new international markets. We will look to replicate the Infinite Fuels joint venture model in other large international markets in the future.”

About MagneGas Corporation

MagneGas® Corporation (MNGA) owns a patented process that converts various renewables and liquid wastes into MagneGas fuels. These fuels can be used as an alternative to natural gas or for metal cutting. The Company’s testing has shown that its metal cutting fuel “MagneGas2®” is faster, cleaner and more productive than other alternatives on the market. It is also cost effective and safe to use with little changeover costs. The Company currently sells MagneGas2® into the metal working market as a replacement to acetylene.

The Company also sells equipment for the sterilization of bio-contaminated liquid waste for various industrial and agricultural markets. In addition, the Company is developing a variety of ancillary uses for MagneGas® fuels utilizing its high flame temperature for co-combustion of hydrocarbon fuels and other advanced applications. For more information on MagneGas®, please visit the Company’s website at http://www.MagneGas.com.

The Company distributes MagneGas2® through Independent Distributors in the U.S. and through its wholly owned distributors, ESSI, Green Arc Supply, and Complete Welding of San Diego. ESSI has 3 locations in Florida, Green Arc 2 locations in Texas and one location in Louisiana, and Complete Welding has one location in southern California. For more information on ESSI, please visit the company’s website at http://www.weldingsupplytampa.com.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events, including our ability to raise capital, or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

For a discussion of these risks and uncertainties, please see our filings with the Securities and Exchange Commission. Our public filings with the SEC are available from commercial document retrieval services and at the website maintained by the SEC at http://www.sec.gov.

News Release
Investor Contacts:
Crescendo Communications
T: 844-589-8760
mnga@crescendo-ir.com

Thursday, March 1st, 2018 Uncategorized Comments Off

$TENX Announces New Scientific Publication of Preclinical Data

MORRISVILLE, N.C.

Preclinical studies find levosimendan improves right heart function
Beneficial treatment for right heart failure secondary to pulmonary hypertension

Tenax Therapeutics, Inc. (Nasdaq: TENX) today announced the publication of a positive preclinical study of levosimendan conducted by Hansen et al in the March 1, 2018, issue of Pulmonary Circulation. The study was titled “Levosimendan improves cardiac function and myocardial efficiency in rats with right ventricular failure” and found that chronic administration of levosimendan improved right heart function. Dr. Hansen and colleagues assessed the effects of levosimendan in an experimental model of right heart failure. The authors conclude the study results support the “potential therapeutic value of chronic levosimendan in treatment RV failure.”

This is the second study published in recent months by Dr. Hansen and colleagues who have investigated the potential benefits of levosimendan treatment for right heart failure secondary to pulmonary hypertension. This group published similar findings in October 2017 in Journal of Cardiovascular Pharmacology in a study titled, “Levosimendan Prevents and Reverts Right Ventricular Failure in Experimental Pulmonary Arterial Hypertension.” The results from this preclinical study resulted in the authors concluding that “Chronic treatment with levosimendan prevents and reverts the development of RV failure and attenuates pulmonary vascular remodeling in a rat model of PAH.”

Observations from these preclinical studies are in keeping with previous clinical trials of levosimendan in pulmonary hypertension patients conducted by Kleber et al in 2009 and Jiang et al in 2017. Each provided evidence that levosimendan may provide benefits to patients with pulmonary hypertension, including those with coexisting right heart failure.

Michael Jebsen, Interim CEO of Tenax Therapeutics stated, “The promising findings reported in the scientific literature provide additional support to our hypothesis that levosimendan has the potential to offer significant benefits in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF) patients through improvements in right heart function. We believe that levosimendan’s unique mechanisms of action will provide an alternative therapy for PH-HFpEF patients who currently have no effective or approved therapies to help manage their disease. Our Phase 2 study for this indication is anticipated to begin in the later part of next quarter.”

About Levosimendan

Levosimendan is a calcium sensitizer that works through a unique triple mechanism of action. It initially was developed for intravenous use in hospitalized patients with acutely decompensated heart failure. It was discovered and developed by Orion Pharma, Orion Corporation of Espoo Finland, and is currently approved in over 60 countries for this indication and not available in the United States. Tenax Therapeutics acquired the North American rights to develop and commercialize levosimendan from Phyxius Pharma, Inc.

About Tenax Therapeutics

Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on licensing, development, and commercialization of drugs that address conditions with high unmet medical need. The Company has a world-class scientific team including recognized global experts in pulmonary hypertension. The Company owns the North American rights to develop and commercialize levosimendan. For more information, visit www.tenaxthera.com.

Caution Regarding Forward-Looking Statements

This news release contains certain forward-looking statements by the company that involve risks and uncertainties and reflect the company’s judgment as of the date of this release. The forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to matters beyond the company’s control that could lead to delays in the clinical study, delays in new product introductions and customer acceptance of these new products, and other risks and uncertainties as described in the company’s filings with the Securities and Exchange Commission, including in its annual report on Form 10-K filed on March 16, 2017, its quarterly report on Form 10-Q filed on November 9, 2017 as well as its other filings with the SEC. The company disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. Statements in this press release regarding management’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

IRTH Communications
Robert Haag, 800-439-1433
TENX@irthcommunications.com

Thursday, March 1st, 2018 Uncategorized Comments Off

$ETST Scientifically Advancing CBD

March 1, 2018

Company committed to scientific validation of CBD efficacy
Produces, markets and sells only the highest quality Full-Spectrum Hemp Oil containing CBD
With new subsidiaries and acquisition, future is increasingly bright

Building on vast anecdotal and mounting scientific evidence, the market for cannabidiol (CBD) products is exploding across the globe. The discovery of the human endocannabinoid system in the 1990s has intensified research and validated many of the anecdotal reports of CBD effectiveness in treating a variety of physical ailments.

Seizing on the immense market opportunity and substantiating efficacy with science, Earth Science Tech, Inc. (OTC: ETST) is focused on the science, research and studies of its high grade hemp CBD oil as a nutraceutical and dietary supplement. Earth Science already markets and sells some of the highest quality and purity Full Spectrum Hemp Oil containing CBD available. The company’s products are formulated using superior supercritical CO2 cold liquid extraction, through which the cannabinoids are kept at the rawest state possible in order to maintain essential therapeutic properties.

Earth Science believes that science is the foundation for the future of not only its high grade hemp CBD oil and its array of products, but also the entire global CBD market. In a commitment to the underlying science, Earth Science has established a research agreement with the University of Central Oklahoma and DV Biologics Laboratory to study and advance the health care benefits of its high grade hemp CBD oil. Research has already indicated that Earth Science CBD nutritional and dietary supplement products are at the top in the industrial hemp space. The company is committed to providing the public with sound scientific research and up-to-date information on the progress of studies being done on its high grade hemp CBD products.

In 2017, Earth Science launched two new subsidiaries, KannaBidioid Inc., to manufacture and distribute vapes/e-liquids and gummy edibles, and Cannabis Therapeutic Inc., to develop proprietary cannabinoid-based nutraceuticals and pharmaceutical products based on its existing CBD patent. The company also acquired Canna Inno Laboratories Inc., which will allow it access to the burgeoning Canadian market and government grants.

Earth Science’s multi-faceted, science-based approach to the development, manufacture and sale of high quality CBD products places the company in a unique and enviable position headed into 2018 and beyond. As Chief Science Officer Michel Aubé, PhD, stated in a January 3, 2018, press release (http://cnw.fm/ak2Pv), “[W]e will clearly be recognized as a leader in cannabinoids research and other health science research arena. Our future is shining bright.”

For more information, visit the company’s website at www.EarthScienceTech.com

More from CannabisNewsWire

About CannabisNewsWire

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Thursday, March 1st, 2018 Uncategorized Comments Off

$DJACF Hiku’s Licensed Cannabis Producer Completes Pre-Sales Inspection

TORONTO, March 1, 2018 – Hiku Brands Company Ltd. (“Hiku” or the “Company“) (CSE: HIKU), Canada’s first vertically-integrated cannabis brand house, is pleased to announce its wholly-owned subsidiary DOJA Cannabis Ltd. (“DOJA“), a licensed cannabis producer under the Access to Cannabis for Medical Purposes Regulations (the “ACMPR“), has completed Health Canada’s (“HC“) Pre-Sales License Inspection of DOJA’s West Kelowna facility. Over a three-day period ending February 15, 2018, HC inspectors were onsite verifying information submitted by DOJA as part of its application and assessing compliance with the applicable sections of the ACMPR prior to license approval. The Pre-Sales License Inspection is the last step prior to the issuance of a Sales License under the ACMPR.

On February 16, 2018, Hiku’s wholly-owned subsidiary, TS Brandco Holdings Inc. (“Tokyo Smoke“), was conditionally awarded one of only four master retail licenses (the “License“) in Manitoba’s highly competitive Request for Proposal process for the right to operate retail cannabis stores (read more here). The License gives Tokyo Smoke the ability to operate legal retail cannabis stores and an online cannabis sales platform in Manitoba. Hiku plans on participating in future licensing processes across the country under the Tokyo Smoke and DOJA brands and growing its national retail footprint.

With the License win in Manitoba, Hiku has increased its internal forecasts for retail demand for its branded cannabis flower and oil, and as a result has decided to accelerate the build-out of DOJA’s second facility (the “FUTURE LAB“) in Kelowna, British Columbia.

With cash and marketable securities of approximately $32.6 million, Hiku is well capitalized to complete the full build-out of the FUTURE LAB and is now targeting a production license for the facility by July 2018 (previously, the Company planned to take a phased approach with an expected completion date of December 2018). True to its name, the FUTURE LAB will incorporate solar power, LED lighting, two-tier vertical farming, a state-of-the-art extraction lab and be capable of producing approximately 4,500 kg/year of dried cannabis flower. The retrofit of the 27,362 sq ft building, with 22,076 sq ft of canopy area over two-tiers, is budgeted to cost approximately $9 million.

About Hiku

Hiku is focused on building a portfolio of iconic, engaging cannabis brands, unsurpassed retail experiences and handcrafted cannabis production. With a national retail footprint led by Tokyo Smoke, craft cannabis production through DOJA‘s ACMPR licensed grow, and Van der Pop‘s female-focused educational platforms, Hiku houses an industry-leading portfolio that sets the bar for cannabis brands in Canada.

Hiku has entered into supply partnerships with Aphria Inc. (TSX: APH) (OTCQB: APHQF) and WeedMD Inc. (TSXV: WMD) to ensure Hiku’s brands will be able to scale in 2018 and beyond.

Statement Regarding Forward-Looking Information

Forward-looking statements in this document include, among others, the Company’s expectation that it will participate in future licensing processes across the country, the construction, costs and timing of the build-out of the FUTURE LAB, the production capacity of the FUTURE LAB following the proposed build-out, and the anticipated timing of receipt of a production license from HC for the FUTURE LAB. By their nature, forward-looking statements are based on the opinions and estimates of management at the date the information is made, and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Hiku is not under any obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

The Canadian Securities Exchange has not approved nor disapproved the contents of this news release.

Abigail Van Den Broek, abby@abigailv.ca, 416-799-8510 or visit HIKU’s website at www.hiku.comCopyright CNW Group 2018

Thursday, March 1st, 2018 Uncategorized Comments Off

$ETST Finalizes Human Trial Plans, CBD-Based Formula for Opioid Addiction

DORAL, Fla., Feb. 28, 2018 — via NetworkWire – Earth Science Tech, Inc. (OTC:ETST) (“ETST” or the “Company”), an innovative biotech company focused on the cannabinoid (CBD), nutraceutical and pharmaceutical fields, as well as on R&D for certain medical devices, today announces that it has finalized the plans for its previously announced human trial to assess the efficacy of the combination of an essential mineral element and full-spectrum cannabinoid industrial hemp oil. The purpose of this nine-month trial is to develop a CBD formulation and methodology for treating opioid addicts, preventing fatal overdoses, and relieving side-effects from withdrawals.

This formulation is expected to increase potency as opposed to the current status quo, which consists solely of essential mineral element therapy (monotherapy) in treating patients with morbid substance abuse and/or dependence.

Globally, there are numerous, promising clinical studies on the potential of cannabinoids for the treatment of substance abuse and psychological disorders. ETST’s new study takes advantage of two of the properties of the Company’s full-spectrum cannabinoids industrial hemp oil that, based on positive feedback from customers and doctors, have demonstrated great success against addiction. ETST’s cannabinoids will be mixed with an essential mineral element, thereby potentially supporting and increasing the action of other drugs and medicinal substances.

The human trial will study substance abuse patients who have undergone drug prescription treatment or dietary supplement monotherapy, full-spectrum cannabinoid monotherapy, and a combination of full-spectrum cannabinoids and a dietary supplement molecule. The patient will receive this treatment sequentially: the first three months with drug prescription treatment monotherapy or dietary supplement monotherapy; the second three months with drug prescription or dietary supplement combined with full-spectrum cannabinoids; and the final three months with full-spectrum cannabinoids.

The project will test the additive nature of full-spectrum cannabinoids with two different forms of an essential mineral element, which will be revealed soon.

Should the potential synergies prove successful, ETST will be positioned to bring innovative new products to the marketplace to counteract the scourge of opioid deaths that is sweeping the United States. ETST intends to produce an over-the-counter nutraceutical product to help addicts resist cravings, as well as a cannabinoid companion for a generic drug to make the treatment more effective while reducing toxicity and adverse side-effects.

ETST Chief Learning Officer Gabriel Aviles and CEO/CSO Dr. Michel Aube, will supervise the project, along with the medical professional advisory board team. The project, along with white paper studies, is expected to be completed by early 2019. This will encourage the Company to pursue clinical studies for at least two years through the remainder of 2019 and 2020, pioneering unprecedented research studies on these two compounds combined.

ETST is currently communicating with its third-party CGMP laboratory on mixing the anti-opioid formula for human trials, and management is in talks with rehab centers interested in participating in the study to some capacity. The Company plans on sharing updates as they progress.

About Earth Science Tech, Inc. (ETST)

To learn more and to buy CBD Hemp Oil, please visit: www.EarthScienceTech.com

About Earth Science Pharmaceutical

To learn more please visit: www.EarthSciencePharmaceutical.com

About Cannabis Therapeutics

To learn more please visit: www.CannabisThera.com

About KannaBidioiD

To learn more please visit: www.KannaBidioiDInc.com

Investor Relations Contact:
Dave Demarest
305.546.7640 Office

Company Contact:
www.EarthScienceTech.com
Nickolas S. Tabraue
President, Director, Chief Operating Officer
305.615.2118 Office
Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Wednesday, February 28th, 2018 Uncategorized Comments Off

$CIIX Releases Stock Dividend Details

ChineseInvestors.com, Inc. Announces Stock Dividend Details Related to the Spinoff of All Hemp-Related Assets Including its China-based Wholly Owned Foreign Enterprise in, XiBiDi (“CBD”) Biotechnology Co. Ltd. and its Wholly Owned United States Subsidiaries, ChineseHempOil.com, Inc. and Hemp Logic, Inc.

SAN GABRIEL, California, February 28, 2018 —

ChineseInvestors.com, Inc. (OTCQB: CIIX) (“CIIX” or the “Company”), the premier financial information website for Chinese-speaking investors, today announces the details of the stock dividends related to the upcoming spinoff of all hemp-related assets including its China-based wholly owned foreign enterprise, CBD Biotechnology Co. Ltd. (“CBD Biotech”) and its wholly owned United States subsidiaries, ChineseHempOil.com, Inc. (“Chinese Hemp Oil”) and Hemp Logic, Inc. (“Hemp Logic”).

Last month, the Company’s subsidiaries achieved combined sales of over $100,000.00 and are well positioned to continue to achieve substantial growth into 2018 and beyond. CIIX plans to spin off all of its hemp related assets including, but not limited to, CBD Biotech, Chinese Hemp Oil and Hemp Logic into a single private company (the “New Company”) with the goal being to bring the New Company into the public market in 12 to 18 months that follow. The New Company will issue one share of stock in the New Company for every four shares of CIIX’s common stock held by investors as of the date of the spinoff, May 31, 2018.

According to CIIX’s CEO, Warren Wang, “We want to provide our shareholders the opportunity to take advantage of this dividend; therefore, we encourage holders of our preferred stock to convert into common prior to May 31, 2018.”

CIIX will continue to oversee the progress of the New Company. CIIX’s CEO, Mr. Wang, and its CFO, Paul Dickman will serve on the board of directors of the New Company. CIIX is also currently evaluating potential independent board members for the New Company and individuals to join the management team.

CIIX has enjoyed success in helping to support various startup companies through its advertising and public relation related support services. Many of those startup companies have gone on to achieve strong stock prices. We look forward to the Company’s spin off continuing this track record of success. Chinese Hemp Oil, Hemp Logic and CBD Biotech represent the Company’s only involvement in the hemp industry, with its hemp-based CBD products; therefore, spinning off these entities will completely remove the parent, CIIX, from its involvement in the hemp industry, leaving the New Company to capitalize on the continuously growing hemp industry and other complimentary ventures.

“This is a great time to spin off CIIX’s CBD focused assets as we continue to explore new ways to expand its core financial services business, including its recent move into the cryptocurrency and blockchain technology industry,” according to ChineseInvestors.com, Inc.’s CFO Paul Dickman.

About ChineseInvestors.com (OTCQB: CIIX)

Founded in 1999, ChineseInvestors.com endeavors to be an innovative company providing: (a) real-time market commentary, analysis, and educational related services in Chinese language character sets (traditional and simplified); (b) advertising and public relation related support services; and (c) retail, online and direct sales of hemp-based products and other health related products.

For more information visit ChineseInvestors.com

Subscribe and watch our video commentaries: https://www.youtube.com/user/Chinesefncom

Like us on Facebook to receive live feeds: https://www.facebook.com/Chinesefncom;

https://www.facebook.com/Chineseinvestors.com.english

Add us on WeChat: Chinesefn or download iPhone iOS App: Chinesefn

Forward-Looking Statements

Contact:
ChineseInvestors.com, Inc.
227 W. Valley Blvd, #208 A
San Gabriel, CA 91776

Investor Relations:
Alan Klitenic
+1-214-636-2548

Corporate Communications:
NetworkNewsWire (NNW)
New York
+1-212-418-1217 Office
Editor@NetworkNewsWire.com

Wednesday, February 28th, 2018 Uncategorized Comments Off

$VSQTF Continues Riding Momentum in a Momentous Year

February 27, 2018

Stock price increased by more than $3.00 in a two-month period
Various acquisitions and partnerships in 2018
Focused on incubating the new century’s technology giants

For more information, visit the company’s website at www.VictorySquare.com

More from NetworkNewsWire

About NetworkNewsWire

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Tuesday, February 27th, 2018 Uncategorized Comments Off

$PVOTF Completes Acquisition of California-Based ERS Holdings, LLC

VANCOUVER, British Columbia, Feb. 27, 2018 —

via NetworkWire – Pivot Pharmaceuticals Inc. (CSE:PVOT) (OTCQB:PVOTF) (“Pivot” or the “Company”) is pleased to announce that the Company has completed the acquisition of ERS Holdings, LLC (“ERS”), a privately-held California company. As previously announced on December 20, 2017, ERS has developed a patented technology called “RTIC” Ready-To-Infuse-Cannabis (the “Patent”), relating to the transformation of cannabis oil into powder for infusion into a variety of food and beverage products such as capsules, K-Cups, stick packs, baked mixes, liquid shots, protein shakes, topicals, lotions, and bottled beverages. ERS has also filed several continuation patents that would allow cannabis powder to be combined with other health and wellness products such as natural sleep-aids, cold medications and vitamins.

Invented by Ross Franklin and Ed Rosenthal, the Patent “relates generally to methods and compositions of matter for enabling concentrated cannabis oil to be stable, emulsifiable and flavorless for use in hot beverages or food by combining cannabis oil with a starch powder or starch-derived powder. Embodiments also relate to a variety of culinary uses for the stabilized, emulsified, flavorless concentrated cannabis oil powder.”

Additionally, Mr. Patrick J. Rolfes has been appointed President of ERS Holdings, LLC, a wholly-owned subsidiary of Pivot. Mr. Rolfes will focus on monetizing the intellectual property (“IP”) and has already received expressions of interest from multi-national beer and spirits companies interested in partnering with Pivot to develop and commercialize THC and/or CBD infused branded products. Further, Mr. Ross Franklin, co-inventor of the Patent, has been appointed as ERS’ Director of Research and Development and will continue to invent new and innovative ways to infuse cannabis into foods and beverages.

Alcoholic beverage sales fell by 15 percent following the introduction of medical marijuana laws in a number of US states, according to a new working paper by researchers at the University of Connecticut and Georgia State University. The study also concludes that marijuana availability can reduce alcohol consumption. Another study by Deloitte suggests that “on sales of recreational marijuana alone, the Canadian marketplace could be as much as C$5B per year to start – a number on par with the Canadian spirit market (whiskey, vodka, rum, etc.). At the upper threshold, which takes into account the people who are ‘likely to consume,’ marijuana sales alone could be as high as C$8.7B, similar to sales generated by wine.”

As a consequence, Molson Coors has acknowledged that legal cannabis is a “risk” to their business, stating in their most recent 10-K that “Although the ultimate impact is currently unknown, the emergence of legal cannabis in certain U.S. states and Canada may result in a shift of discretionary income away from our products or a change in consumer preferences away from beer. As a result, a shift in consumer preferences away from our products or beer or a decline in the consumption of our products could result in a material adverse effect on our business and financial results.”

Dr. Patrick Frankham, CEO of Pivot, stated that “the RTIC family of patents will be transformational for the food and beverage industry. Based on our interaction with key players in the beverage market, we anticipate that there will be a significant substitution in consumer choices towards cannabis infused drinks. With this acquisition, we have positioned Pivot to be at the forefront of this enormous new market. Closing this transaction will enable us to further engage interested parties to work with us on developing the full potential of these Patents. Pivot intends to monetize the Patents as quickly as possible and thus I am delighted that Patrick Rolfes and Ross Franklin have joined the Pivot team to accelerate the process.”

Dr. Frankham also stated that “today’s related financing confirms that our vertically integrated cannabis business model is differentiated in the Canadian marketplace and recognized by a strong sponsorship from a sophisticated institutional investor. The Company will continue working with its financial advisor, Origin Merchant Partners, to successfully close our pending acquisitions and aggressively execute the remainder of our business plan in 2018/2019.”

Convertible Debenture Units

Pivot also announced today a private placement offering of senior secured convertible debentures (“Convertible Debentures”) of the Company with a conversion price of $1.74 per common share for aggregate gross proceeds of $5,000,000 (the “Offering”). The net proceeds received by the Company will be used to, among other things, fund working capital and general corporate purposes, including but not limited to, development of its pipeline of products and intellectual property acquisitions.

The Company has entered into an agreement with an institutional investor with respect to the Offering, whereby the institutional investor has agreed to subscribe for up to $5,000,000 aggregate principal amount of Convertible Debentures. Closing of the Offering is subject to the satisfaction of customary conditions, including the receipt of all requisite regulatory approvals.

The Convertible Debentures will bear interest at the rate of 10% per annum, payable quarterly, will mature 12 months following the date of their issuance and will be convertible at the option of the holder for a period of 12 months into common shares of the Company (“Common Shares”) at a conversion price of $1.74 per Common Share (the “Conversion Price”), subject to adjustment of the Conversion Price in certain events.

Beginning on the date that is four months and one day following the issuance of the Convertible Debentures, the Company may force the conversion of the principal amount of the then outstanding Convertible Debentures at the Conversion Price on not less than 30 days’ notice should the daily volume weighted average trading price of the Common Shares be greater than $2.50 for any 20 consecutive trading days on the Canadian Stock Exchange, or such other exchange as the Common Shares are principally traded.

The Convertible Debentures shall be offered and sold by way of private placement to “accredited investors” within the meaning of NI 45-106 – Prospectus Exemptions and other exempt purchasers (i) in Canada, and (ii) outside Canada and the United States on a basis which does not require the qualification or registration of any of the Convertible Debentures or the Company. The Convertible Debentures and the Common Shares issuable upon the conversion of the Convertible Debentures will be subject to a statutory four month and one day hold period.

Subject to the satisfaction of customary of conditions, the Offering is expected to be completed on or about February 28, 2018.

About Pivot Pharmaceuticals Inc.

Cautionary Statement

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information in this news release constitutes forward-looking statements under applicable laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as anticipate, believe, estimate, expect, intend, and similar expressions, as they relate to Pivot, ERS, or their respective management, identify forward-looking statements. Forward-looking statements in this news release include, but are not limited to, statements with respect to accretive earnings, anticipated revenue and costs synergies associated with the acquisition of ERS, statements with respect to internal expectations, estimated margins, expectations for future growing capacity and costs, the completion of any capital project or expansions, the timing for the completion of pending acquisitions, the ability of the Company to complete a financing in order to satisfy its financial obligations under the pending acquisitions and expectations with respect to future production costs. In particular, there can be no assurance that the pending acquisitions will be completed. Forward looking statements are based on certain assumptions regarding ERS, including expected growth, results of operations, performance, industry trends and growth opportunities. While the Company considers these assumptions to be reasonable, based on information currently available, they may prove to be incorrect. Readers are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements also necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; the possibility that the Company be unable to successfully integrate ERS as described herein; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the medical marijuana industry in Canada generally, income tax and regulatory matters; the ability of the Company to implement its business strategies; competition; crop failure; currency and interest rate fluctuations and other risks. Any forward-looking statements or facts (including financial information) related to ERS discussed or disclosed herein are derived from information obtained directly from ERS and publicly available sources and has not been independently verified by the Company. Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

Contact:
Pivot Pharmaceuticals Inc.
Patrick Frankham, PhD, MBA
Chief Executive Officer
Tel: (514) 943-1899
Email: Info@PivotPharma.com

Corporate Communications Contact:

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Tuesday, February 27th, 2018 Uncategorized Comments Off

$DJACF CannabisNewsAudio Audio Press Release on Canadian Cannabis Market

New York, New York–(Newsfile Corp. – February 27, 2018) – CannabisNewsAudio announces the Audio Press Release (APR) titled “Key Companies That Will Remap Canada’s Cannabis Retail Industry,” featuring Hiku Brands Company Ltd. (CSE: HIKU) (OTC: DJACF).

To hear the NetworkNewsAudio version, visit: http://nnw.fm/Nm9A2

To read the original editorial, visit: http://nnw.fm/l3Kun

Although the name HIKU is new, the brands behind it are well-known and have interesting back stories. Tokyo Smoke was named “best brand” at the inaugural Cannabis Industry Awards in December 2017, and in January 2018 the company joined forces with Doja Cannabis Company to create HIKU. HIKU is led by CEO Alan Gertner and President Trent Kitsch, who founded the best-selling men’s brand, SAXX Underwear.

The cannabis industry is growing at a rapid pace. While powerful players are teaming up to establish brand presence and formulate creative ways to differentiate themselves, the smaller contenders will begin to get weeded out. With Manitoba’s major retail cannabis players now clear, the stage is set for companies to continue their push toward becoming Canada’s first dominant cannabis retailers. HIKU, with shares trading over $2.50 and an estimated market cap topping $300 million, is definitely one to watch.

About Hiku Brands Company Ltd.

Hiku is focused on handcrafted cannabis production, immersive retail experiences, and building a portfolio of iconic, engaging cannabis lifestyle brands. Hiku is differentiated as the only Canadian craft cannabis producer with a significant national retail footprint and a growing brand house including premium cannabis lifestyle brands DOJA, Tokyo Smoke, and Van der Pop. Hiku’s wholly-owned subsidiary, DOJA Cannabis Ltd., is a federally licensed producer pursuant to the ACMPR, owning two production facilities in the heart of British Columbia’s Okanagan Valley. The company operates a network of retail stores selling coffee, clothing and curated accessories, across British Columbia, Alberta and Ontario. For more information, visit the company’s website at www.Hiku.com

About CannabisNewsWire (CNW)

CannabisNewsWire (“CNW”) is a specialized information service that (1) aggregates cannabis news, (2) provides CannabisNewsBreaks that quickly updates investors in the space, (3) enhances corporate press releases, (4) helps companies with distribution and optimization of social media, and (5) delivers comprehensive corporate communication solutions. CNW is uniquely positioned in the cannabis market with a strong team of journalists and writers who can help private and public companies reach a wide audience of investors, consumers, journalists and the general public through our ever-growing dissemination network of more than 5,000 key syndication outlets. CNW is bringing unparalleled visibility, recognition and content to the cannabis industry.

For more information please visit https://wwwCannabisNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://CNW.fm/Disclaimer

Forward-Looking Statements

CNW Corporate Communications Contact:

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Tuesday, February 27th, 2018 Uncategorized Comments Off

$CIIX Recognizes Untapped CBD Market for Chinese-Speaking Individuals

February 27, 2018

ChineseInvestors.com provides first platform for Chinese-centric CBD market
The company boasts real-time services in Chinese character sets
ChineseInvestors.com launched CBD navigation application

Founded in 1999, ChineseInvestors.com, Inc. (OTCQB: CIIX) aims to be a leading financial information website that provides real-time market commentary, analysis and education-related services to Chinese-speaking investors through its dynamic financial website, www.Chinesefn.com. ChineseInvestors.com, Inc. went public on the OTCQB Venture Market in January 2012, under the symbol CIIX (http://cnw.fm/RB2Yo).

Having recognized the unprecedented opportunities that lie within the American cannabis industry, the company started laying the foundations to capitalize on the ever-growing demand for cannabidiol-based nutrition and health products. The end of 2016 marked the company’s implementation of plans for its new website, its mobile application and its online distribution of CBD oils for the booming global industry of medical marijuana. Although marijuana use is illegal within the borders of China, cannabis-based oils that include hemp-based CBDs are legal. This unique opportunity opens a potential market of nearly two billion people for the company.

Following the launch of ChineseCBDoil.com in early 2017, the company noted that it was the first online CBD health products store in the Chinese language. The website shows a variety of nutritional supplements containing CBD, including soft gels, capsules and concentrates marketed to Chinese-speaking customers worldwide. It is the company’s intention to open up a retail store in the predominantly Chinese community of San Gabriel, California, which is also where the company’s headquarters is located (http://cnw.fm/0fyWG).

ChineseInvestors.com also launched the world’s first Chinese-language-based mobile cannabis navigation application. This ‘Yelp’ style social media application is set to contain a database of marijuana dispensaries and cannabis strains, along with platforms to review and discuss various cannabis products and maps that show the locations of medical and recreational cannabis dispensaries. Alongside this, the application is set to offer cannabis business summaries and reports from Los Angeles, as well as other large cities, in an effort to provide customers with access to the best recommendations for local marijuana products. The application has been approved by the Apple store and is available for download.

In an effort to assist patients with Alzheimer’s disease, epilepsy, cirrhosis of the liver and a range of other physical and mental ailments, ChineseInvestors.com will continue its focus on investment in both the distribution and the R&D of CBD medicine and health products. With the company’s base of over 100,000 users, alongside its brand value built over the past 18 years, its mission is to become the leading Chinese medical marijuana-focused publicly traded company.

China has nearly 10 million patients that suffer from epilepsy, placing it among the most common diseases that Chinese researchers are eager to cure. Currently, in China, epilepsy cannot be wholly cured, with patients relying heavily on drugs or Chinese herbs to temporarily control the illness. In the United States, epilepsy has been successfully addressed through specialized surgical treatment. However, this option comes with a high risk factor. As a result, a majority of Chinese patients are inclined to seek conservative treatment methods in the field of Western medicine. CBD oil, therefore, has a huge potential within the market space for the treatment of epileptic cases that are located in the mainland or overseas.

Regarding clinical trials and research, ChineseInvestors.com intends to further study the efficacy of CBD oil for the treatment of the above-mentioned illnesses. Apart from that, the company will invest in CBD drug R&D enterprises with the goal of developing various CBD drugs that show positive results when used to combat epilepsy and Alzheimer’s disease. The application period for new drugs of this nature in China is two to four years, which is notably shorter than that of the FDA. It is the company’s goal to be the first company in China to use CBD oil to help mitigate the suffering of patients with epilepsy and Alzheimer’s disease.

The company also offers support services to its various partners, consultative services to smaller private companies that are considering becoming public entities and advertising and public relations-related support services.

With the further legalization of medical marijuana supported by studies, greater market sizes can be expected. With fewer drug side effects and further drug development, it is likely that the number of CBD products will increase, with more people likely to opt for these safer treatments. On a wider scale the problem of acute and chronic pain can be combatted, resulting in fewer production losses in the workplace.

For more information, visit the company’s website at www.ChineseInvestors.com

More from CannabisNewsWire

About CannabisNewsWire

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Tuesday, February 27th, 2018 Uncategorized Comments Off

$NXTD & $DFS Partner to Extend Payments to #IoT Devices, @FitPayInc

Agreement gives Discover cardholders access to the latest payment technology for more secure and convenient contactless payments

RIVERWOODS, Illinois and MELBOURNE, Florida, February 26, 2018 —

Discover Financial Services and FitPay, Inc., a wholly owned subsidiary of NXT-ID, Inc., today announced a network services agreement to allow devices that are integrated with the FitPay Payment Platform^[^TM^] to provision tokenized payment credentials through Discover^® Digital Exchange (DDX). The agreement enables Discover cardholders, along with alliance partner cards, to easily make contactless payment transactions at retail locations with wearable or Internet of Things (IoT) devices that include payment capabilities powered by FitPay^[^TM^].

“With the advancements of mobile technology, the way customers interact with merchants is being re-imagined with an eye toward more secure and convenient methods of payment,” said Diane Offereins, Discover’s president of payment services. “This integration with FitPay is one more way in which Discover is continuing to enhance the payment experience and provide more options for our cardholders on how and where they pay.”

Under the agreement, FitPay’s payment and digital wallet platform will be integrated with the Discover tokenization platform, DDX. FitPay’s platform enables manufacturers of IoT and wearable devices to add contactless payment capabilities to their products, making it possible for consumers to pay for goods and services at near field communication (NFC)-enabled point-of-sale terminals with a simple tap. The platform uses tokenization, a payment security technology that replaces cardholders’ account information with a unique digital identifier (“payment token”), to transact more secure contactless payments. The agreement gives Discover cardholders access to the latest contactless payment technology.

“Consumers should have options in how they pay, and this agreement makes cutting-edge payment devices available to Discover cardholders,” said Michael Orlando, COO of NXT-ID and president of FitPay, Inc. “Making payments easy, secure and frictionless requires building an extensive ecosystem. Discover is a unique and important part of that ecosystem, and we are very pleased be able to make the network available to devices on the FitPay Platform.”

Manufacturers of 15 IoT and wearable devices are currently integrating with the FitPay Payment Platform. Product announcements from manufacturers of the devices integrating with the FitPay platform are anticipated in 2018.

About Discover

Discover Financial Services (NYSE: DFS) is a direct banking and payment services company with one of the most recognized brands in U.S. financial services. Since its inception in 1986, the company has become one of the largest card issuers in the United States. The company issues the Discover card, America’s cash rewards pioneer, and offers private student loans, personal loans, home equity loans, checking and savings accounts and certificates of deposit through its direct banking business. It operates the Discover Network, with millions of merchant and cash access locations; PULSE, one of the nation’s leading ATM/debit networks; and Diners Club International, a global payments network with acceptance in more than 185 countries and territories. For more information, visit: http://www.discover.com/company.

NXT- ID, Inc. and FitPay, Inc.

NXT-ID, Inc. (NASDAQ: NXTD) provides a comprehensive platform of technology products and services that enable the Internet of Things (IoT). With extensive experience in access control, biometric and behavior-metric identity verification, security and privacy, encryption and data protection, payments, miniaturization and sensor technologies, NXT-ID develops and markets groundbreaking solutions for payment and IoT applications. Its industry-leading technology products and solutions include MobileBio®, a suite of biometric solutions that secure consumers’ mobile platforms, the Wocket™, a next-generation smart wallet and the Flye, a digital credit card developed in collaboration with WorldVentures. NXT-ID includes three mobile and IoT-related subsidiaries: LogicMark, LLC, a manufacturer and distributor of non-monitored and monitored personal emergency response systems (“PERS”) sold through dealers/distributors and the United States Department of Veterans Affairs; FitPay, Inc., a proprietary technology platform that delivers end-to-end solutions to device manufacturers for contactless payment capabilities, credential management, authentication and other secure services within the IoT ecosystem, and 3D-ID LLC, which is engaged in biometric identification and authentication. Learn more about NXT-ID at http://www.nxt-id.com. NXT-ID Inc. Corporate Contact: info@nxt-id.com. FitPay and the FitPay Payment Platform are trademarks of FitPay, Inc.

Forward-Looking Statements for NXT-ID: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company’s business strategy. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the Company’s ability to implement its long range business plan for various applications of its technology; the Company’s ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company’s technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission.

Media Contacts:
Chris Orlando
FitPay, Inc.
chris@fit-pay.com
760-468-7273

Jeremy Borling
Discover
jeremyborling@discover.com
224-405-4252
@Discover_News

Monday, February 26th, 2018 Uncategorized Comments Off

$DJACF CannabisNewsWire Publication on Cannabis Innovators, Canadian Retail Industry

February 23, 2018

CannabisNewsWire Editorial Coverage: Out of 120 applicants, Manitoba recently awarded four master retail licenses, a monumental action as Canada prepares to legalize cannabis for recreational use this summer. The entities that now hold prized licenses to retail pot and its associated paraphernalia in the province are: Tokyo Smoke, a subsidiary of HIKU Brands (CSE:HIKU; OTCBB: DJACF) (DJACF Profile); a consortium of Delta 9 Cannabis Inc. and Canopy Growth Corp. (TSX: WEED) (OTC: TWMJF); National Access Cannabis (CSE: NAC) (OTC: NACNF); and 10552763 Canada Corporation. One key industry player that missed out on this licensing opportunity is MedReleaf (TSE: LEAF) (OTC: MEDFF). These licenses open the doors to considerable recreational retail revenue potential, and investors with foresight were quick to take action, with Aphria (TSX: APH) (OTC: APHQF) and Koicha Partners LP investing millions into the big four’s newest presence, HIKU.

New name, established brand

Although the name HIKU is new, the brands behind it are well-known and have interesting back stories. Tokyo Smoke was named “best brand” at the inaugural Cannabis Industry Awards in December 2017, and in January 2018 the company joined forces with Doja Cannabis Company to create HIKU. HIKU is led by CEO Alan Gertner and President Trent Kitsch, who founded the best-selling men’s brand, SAXX Underwear.

Gertner ran a $100 million business as head of an Asia-Pacific-wide sales team during his tenure in corporate strategy at Google. When he found that what he thought was his dream job was less than fulfilling, he shifted gears and co-founded Tokyo Smoke with his father Lorne Gertner, formerly PharmaCan chairman (now Cronos Group), who was dubbed the ‘Godfather of Canadian Cannabis’.

Tokyo Smoke is a seasoned retailer, already running stores online and several successful brick-and -mortar shops, selling a range of experiential products that feature the creative use of cannabis. Established already in key markets like Toronto and Calgary, Tokyo Smoke’s cannabis will soon be on shelves in legal recreational dispensaries in the United States.

East meets West in merging of cannabis retail and production minds

Partnering with Doja Cannabis, a seasoned Kelowna-based pot producer, was Gertner’s first foray into production. The strategy of merging minds with industry expertise in producing and retailing pot brought Gertner, based in the east, and Kitsch, based in the west, to a new market in the Manitoban middle ground.

The cannabis industry is growing at a rapid pace. While powerful players are teaming up to establish brand presence and formulate creative ways to differentiate themselves, the smaller contenders will begin to get weeded out. With Manitoba’s major retail cannabis players now clear, the stage is set for companies to continue their push toward becoming Canada’s first dominant cannabis retailers. HIKU, with shares trading over $2.50 and an estimated market cap topping $300 million, is definitely one to watch.

Comparables:

Aphria (NASDAQ: APHQF) (TSE: APH) was founded in 2011 and is headquartered in Leamington, Ontario. The company calls itself one of the lowest-cost producers of marijuana, and produces dry cannabis, as well as cannabis oil of varying qualities and strength. Its cannabis is 100 percent greenhouse grown. Aphria’s estimated market cap is over $2 billion.

Canada’s largest producer, Canopy Growth (OTC: TWMJF) (TSE: WEED), has a market cap of more than $4 billion, with shares currently trading over $22, a 61.3% increase over the last three months. Formerly known as Tweed Marijuana Inc., Canopy Growth was founded by Bruce Linton in 2014, and is based in Smiths Falls, Ontario. Canopy Growth is the first federally regulated, publicly traded cannabis producer in North America. It operates numerous production facilities across Canada and around the world with over 700,000 square feet of production licensed under Canada’s medical cannabis framework.

National Access Cannabis (OTC: NACNF) (CSE: NAC) National Access Cannabis’ market cap is over $135 million; stock is trading over $1. The company operates medical cannabis care centers across Canada, National Access is adapting its established medical clinic model to meet the needs of the Manitoba retail market. National Access works alongside Health Canada and Licensed Producers to help qualifying patients gain access to their license. After receiving the Manitoba retail National Access announced it intends to deepen its relationships with CannaRoyalty Corp. and Cannabis Wheaton Income Corp.

MedReleaf (TSE: LEAF) (OTC: MEDFF) was voted Top Licensed Producer at the Lift Canadian Cannabis Awards. MedReleaf is an Ontario- based, R&D-driven company dedicated to innovation, and delivering products to the global medical market, and providing brands and product assortment for the recreational consumer market. MedReleaf’s market cap is currently over $2.26 billion.

For a more in-depth look into HIKU Brands, visit HIKU Brands (CSE:HIKU; OTCBB: DJACF) or read the FULL Report: Cannabis Investors Need Three M’s To Success: Money, Moxie, and Management

About CannabisNewsWire

Receive Text Alerts from CannabisNewsWire: Text “Cannabis” to 21000

For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by CNW are solely those of CNW. Readers of this Article and content agree that they cannot and will not seek to hold liable CNW for any investment decisions by their readers or subscribers. CNW is a news dissemination and financial marketing solutions provider and is NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, CNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CNW undertakes no obligation to update such statements.

Monday, February 26th, 2018 Uncategorized Comments Off

$PBIO to Create Unique Analytical System Using Patented Pressure Cycling Technology

February 21, 2018

The two companies entered co-marketing and distribution agreement to be implemented worldwide
Pressure BioSciences’ high pressure generator technology can improve optical spectroscopy accuracy and data collection with potentially far-reaching impact on drug development
The joint technology will be promoted to scientists all over the world and is expected to generate increased sales starting this year

A leading developer and provider of innovative high pressure-based solutions to the global life sciences industry, Pressure BioSciences, Inc. (OTCQB: PBIO) has entered a two-year agreement with ISS, Inc., a prominent designer and manufacturer of advanced scientific instruments with more than 30 years of experience in the field. Under the agreement, the two companies will join their marketing and distribution efforts worldwide, as well as their own technologies to create an advanced high pressure optical spectroscopy system that’s expected to generate significant data that could be critical to the discovery and development of new biopharmaceutical diagnostics and drugs, according to a Pressure BioSciences press release issued on February 14, 2018 (http://nnw.fm/zf2UE).

Optical spectroscopy is typically used by scientists all over the world as a powerful analytical method to generate and gather information about the composition of biological molecules. The collected data have multiple applications ranging from the design of new drugs to the development of preventive strategies against certain diseases. However, with high pressure optical spectroscopy, scientists have access to a more unique and effective way to study molecular interactions instantaneously and with a better control of reversibility and irreversibility, due to the easily adjustable duration and amount of applied pressure. This can greatly improve the speed and accuracy of data collection, helping scientists better understand how biological molecules function and interact, with a significant impact on the discovery and development of improved drugs and diagnostics.

ISS is confident that, by using Pressure BioSciences’ patented and game-changing pressure cycling technology (“PCT”) with its optical cell systems instead of current manual pressure generators, scientists will be able to “visualize biochemical reactions as they are happening in the pressure cell,” as noted by ISS President Dr. Ben Barbieri in a news release. “The Pressure BioSciences pressure generators will also facilitate automated and significantly faster data collection. Such systems could potentially have a significant and far-reaching impact on drug development and other important areas of biomedical research worldwide,” he added.

“This powerful combination of technologies will be promoted to scientists worldwide by both Pressure BioSciences and ISS, with the combined system expected to drive an increase in sales this year and beyond,” commented Dr. Nate Lawrence, PBIO VP of Marketing and Sales.

The ISS Agreement is the latest in a series of acquisitions and collaborations that Pressure BioSciences has entered into over the last few months, including, most notably, the acquisition of BaroFold, Inc.’s assets in December of last year and its entry into a strategic partnership with Phasex Corporation in October 2017. The BaroFold acquisition has significantly increased the company’s intellectual property estate by eight issued patents and several others that are pending, as noted by CEO Richard T. Schumacher on a ‘Stock Day’ podcast (http://nnw.fm/E65rm).

With Phasex, the collaboration has allowed Pressure BioSciences to enter the fast-growing nanoemulsions market, where its proprietary PCT-based Ultra Shear Technology can be used with Phasex’s Supercritical Fluid processing to generate water-soluble, fully stable nanoemulsions. Ensuring stability of nanoemulsions has been a challenge until now, but this strategic collaboration has every chance to change that, leading to the further expansion of an already large market and an increase in the number of potential nanoemulsion applications in industries ranging from pharmaceuticals, nutraceuticals, cosmetics, paints and industrial lubricants to food and even medical cannabis (e.g., CBD).

Unlike most commercially-available emulsions, which tend to be unstable and sometimes inappropriate for human use due to a high amount of surfactants required, nanoemulsions have been shown to improve absorption, enhance stability, exhibit higher bioavailability, contain reduced amounts of surfactants and present multiple other advantages. Pressure BioSciences is confident that, with its patented Ultra Shear Technology, it will be able to develop commercial-scale nanoemulsions that require less emulsifying events, or even none at all.

For more information, visit the company’s website at www.PressureBioSciences.com

More from NetworkNewsWire

About NetworkNewsWire

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Monday, February 26th, 2018 Uncategorized Comments Off

Uncategorized

Patent extends proprietary position of M207 to 2037

DEADWOOD, S.D. & PORTLAND, Ore.

European Government Funding Expected to Expand Scope of German-Based Biofuels Pilot Program in 2018

MORRISVILLE, N.C.

Agreement gives Discover cardholders access to the latest payment technology for more secure and convenient contactless payments

TraderPower Featured Companies

Top Small Cap Market News

Recent Posts

Recent Comments

Archives

Categories

Meta